ImPact Biotech is focused on the development and launch of Padeliporfin VTP (Vascular Targeted Photodynamic) therapy for the treatment of solid tumors. The company is headquartered in Israel, with presence in Luxembourg, France and USA, as well as its own GMP-certified (Good Manufacturing Practice) facility and research center in Israel.
ImPact Biotech holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York), to develop and commercialize drugs and related technologies used in VTP.
Company Details
- Employees
- 40
- Founded
- -
- Address
- 16 Einstein St., Ness Ziona,israel 7403622,israel
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.stebabiotech.com
- HQ
- Ness Ziona, Israel
Impact Biotech Questions
Impact Biotech's website is http://www.stebabiotech.com
Impact Biotech's LinkedIn profile is https://il.linkedin.com/company/stebabiotech-s-a
Impact Biotech has
40 employees.
View email and phone details for 40
employees at Impact Biotech.
Impact Biotech's industry is
Biotechnology Research
Impact Biotech's top competitors are
Purple Biotech,
Danyel Biotech,
Immpact Bio,
Biolinerx,
Da-Ta Biotech Ltd,
Mediwound,
Evogene,
Gamida Cell Ltd.,
Jaxbio,
Denovai Biotech.
Impact Biotech's categories are Biotechnology Research
Impact Biotech's founding year is 2022
